Impact of Pharmaceutical Care Plan on Clinical Outcomes in Pregnant Women with Gestational Diabetes Mellitus: A Prospective Interventional Study

Background: Gestational diabetes mellitus (GDM) is one of the most common pregnancy complications, associated with adverse maternal and neonatal outcomes. Pharmaceutical care, including structured patient education and medication management, has been shown to improve treatment adherence, glycemic control, and maternal quality of life in GDM.¹˒² Aim: To analyze the impact of a pharmaceutical care plan on pregnant women with GDM through quantitative and qualitative outcomes. Methods: A prospective interventional study was conducted for three months in a tertiary care hospital. Of 100 screened participants, 50 pregnant women with poor adherence and low knowledge scores were enrolled and equally divided into intervention and control groups. The intervention group received structured counseling and a patient information leaflet (PIL). Outcomes assessed included glycated hemoglobin (HbA1c), quality of life (QOL; DSQOL, ADS), and medication adherence (MMAS-8). Statistical significance was set at p < 0.05.Results: After intervention, HbA1c improved significantly in the intervention group compared to control (p < 0.05). Quality of life scores improved across physical, emotional, and social domains in the intervention group, while no notable changes were seen in the control group. Adherence improved markedly in the intervention group, whereas the control group showed minimal change. Conclusion: Pharmaceutical care interventions significantly improved glycemic control, adherence, and quality of life in women with GDM. These findings highlight the importance of integrating pharmacists into multidisciplinary antenatal care teams to optimize maternal and neonatal outcomes.